Relay Therapeutics, Inc.

NASDAQ:RLAY

Biotechnology

Healthcare
$16.51 +2.63%

+$0.41 today

Market cap
$3.65B
Beta
1.75
P/E (TTM)
-10.5
EPS (TTM)
-$1.52
52W Low $3.03High $17.47

Volume 2.43M

Average 3.70M

RLAY Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Relay Therapeutics, Inc.NASDAQ: RLAY

Total Equity · Q2 FY2026 · quarter ended Jun 2026

Total equity rises 33.7% from a year ago

Total equity stood at $890.01M at the end of Q2 FY2026, up 33.7% from a year earlier and up 38.6% from the prior quarter. Over 3 fiscal years it compounded at -15.8% a year.

Context

  • Total equity amounted to 92.0% of total assets at the end of Q2 FY2026, up 0.7 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +33.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$890.01M+38.6% QoQ
Last fiscal yearDec 2025
$567.06M-27.1% YoY
Year agoJun 2025
$665.66M+33.7% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.7%——
1 year-27.1%——
3-year CAGR-15.8%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
567.06M USD
Year-over-year change
-27.1%
4-year CAGR
-10.9%

Total Equity vs competitors

How RLAY compares with its peers on the latest reported figures

  • RLAY's Jun 2026 total equity of $890.01M is the 7th highest of the 11 companies compared; the peer median is $927M.
  • Its year-over-year change of +33.7% is the 8th highest of 11, against a peer median of +57.7%.
  • Total equity amounts to 92.0% of total assets for RLAY, versus a peer median of 91.7%.
RLAY Competitors Peer median
Total Equity for RLAY and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RVMDRevolution Medicines, Inc.Jun 2026$2.61B +39.7%+33.5%60.3%
KYMRKymera Therapeutics, Inc.Jun 2026$1.51B +55.4%+47.7%91.7%
TNGXTango Therapeutics, Inc.Sep 2026$980.17M +512.5%+11.5%94.8%
NRIXNurix Therapeutics, Inc.Aug 2026$968.31M +160.1%+21.1%81.0%
IDYAIDEAYA Biosciences, Inc.Mar 2026$937.27M -8.5%+43.0%91.0%
ERASErasca, Inc.Sep 2026$916.74M +163.5%-7.6%91.8%
RLAYRelay Therapeutics, Inc.Jun 2026$890.01M +33.7%-15.8%92.0%
ORICORIC Pharmaceuticals, Inc.Mar 2026$415.56M +89.1%+20.0%95.1%
TYRATyra Biosciences, Inc.Mar 2026$387.58M +19.8%+0.2%94.1%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$323.98M +60.0%+20.8%92.8%
PRLDPrelude Therapeutics IncorporatedMar 2026$60.18M -41.7%-29.4%50.3%
Peer median (excluding RLAY) $927M+57.7%+20.4%91.7%

Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents280.12M151.79M143.74M124.29M84.02M
Short-term Investments677.95M847.12M606.35M657.04M470.5M
Net Receivables4.94M5.22M000
Inventory012.11M000
Other Current Assets1.76M3.26M3.32M10.53M5.97M
Total Current Assets976.24M1.02B770.1M809.2M578.28M
Property, Plant & Equipment (Net)27.32M75.39M68.87M57.67M41.72M
Goodwill00000
Intangible Assets2.3M2.3M2.3M2.3M0
Long-term Investments02.58M2.71M01.34M
Tax Assets0(2.58M)000
Other Non-current Assets2.58M2.58M02.12M0
Total Non-current Assets32.2M80.27M73.88M62.09M43.05M
Total Assets1.01B1.1B843.98M871.3M621.33M
Account Payables8.28M10.58M9.21M14.1M7.71M
Short-term Debt00000
Tax Payables00000
Deferred Revenue248K007.68M0
Other Current Liabilities989K26.15M1.91M2.1M463K
Total Current Liabilities24.32M63.71M30.27M50.73M25.58M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities65.26M32.38M13.21M00
Total Non-current Liabilities86.31M85.84M61.71M42.78M28.69M
Total Liabilities110.64M149.55M91.98M93.5M54.27M
Common Stock109K121K127K168K168K
Retained Earnings(768.1M)(1.06B)(1.4B)(1.74B)(2.01B)
Accumulated OCI(1.09M)(10.42M)(196K)(991K)733K
Other Stockholders Equity00000
Minority Interest00000
Total Equity897.81M950.22M752M777.79M567.06M
Total Debt22.9M57.74M53.47M48.5M32.46M
Net Debt(257.22M)(94.05M)(90.27M)(75.79M)(51.56M)

Relay Therapeutics, Inc.

NASDAQ:RLAY

Intrinsic Alpha fair value

Locked

Current Price

$16.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.